Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on October 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on September 22nd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 10/1/2025.
• Sold $1,001 – $15,000 in shares of Amdocs (NASDAQ:DOX) on 10/1/2025.
• Purchased $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 9/30/2025.
• Sold $15,001 – $50,000 in shares of Fortive (NYSE:FTV) on 9/30/2025.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 9/30/2025.
• Purchased $1,001 – $15,000 in shares of APi Group (NYSE:APG) on 9/30/2025.
• Sold $1,001 – $15,000 in shares of GoDaddy (NYSE:GDDY) on 9/30/2025.
• Purchased $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 9/30/2025.
• Purchased $1,001 – $15,000 in shares of CoStar Group (NASDAQ:CSGP) on 9/30/2025.
• Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 9/30/2025.

BridgeBio Pharma Stock Performance

Shares of NASDAQ:BBIO opened at $56.50 on Wednesday. The company has a market cap of $10.80 billion, a P/E ratio of -13.81 and a beta of 1.36. BridgeBio Pharma, Inc. has a one year low of $21.72 and a one year high of $57.47. The business’s 50-day simple moving average is $51.40 and its 200 day simple moving average is $43.22.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Tuesday, August 5th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The company had revenue of $110.57 million during the quarter, compared to analyst estimates of $98.46 million. The business’s revenue for the quarter was up 4999.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.39) EPS. Analysts predict that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Insider Buying and Selling at BridgeBio Pharma

In related news, Director Andrea Ellis sold 17,167 shares of the business’s stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $49.00, for a total transaction of $841,183.00. Following the completion of the transaction, the director owned 18,589 shares in the company, valued at $910,861. The trade was a 48.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Charles J. Homcy sold 250,000 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $46.05, for a total value of $11,512,500.00. Following the transaction, the director owned 966,674 shares of the company’s stock, valued at $44,515,337.70. This represents a 20.55% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 597,913 shares of company stock worth $29,034,227. 18.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. boosted its position in BridgeBio Pharma by 29.4% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 30,802 shares of the company’s stock valued at $1,065,000 after purchasing an additional 6,997 shares during the period. GAMMA Investing LLC boosted its position in BridgeBio Pharma by 71.0% during the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock valued at $32,000 after purchasing an additional 382 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in BridgeBio Pharma during the 1st quarter valued at approximately $251,000. Baird Financial Group Inc. acquired a new position in BridgeBio Pharma during the 1st quarter valued at approximately $1,429,000. Finally, Moss Adams Wealth Advisors LLC boosted its position in BridgeBio Pharma by 49.2% during the 2nd quarter. Moss Adams Wealth Advisors LLC now owns 24,172 shares of the company’s stock valued at $1,044,000 after purchasing an additional 7,970 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Analyst Upgrades and Downgrades

BBIO has been the topic of several analyst reports. Bank of America lifted their price objective on BridgeBio Pharma from $50.00 to $54.00 and gave the stock a “buy” rating in a report on Wednesday, June 25th. JPMorgan Chase & Co. lifted their price objective on BridgeBio Pharma from $55.00 to $70.00 and gave the stock an “overweight” rating in a report on Wednesday, September 3rd. Scotiabank lifted their price objective on BridgeBio Pharma from $55.00 to $57.00 and gave the stock a “sector outperform” rating in a report on Wednesday, August 6th. Jefferies Financial Group initiated coverage on BridgeBio Pharma in a report on Monday, July 14th. They set a “buy” rating and a $70.00 price objective on the stock. Finally, Citigroup lifted their price objective on BridgeBio Pharma from $58.00 to $67.00 and gave the stock a “buy” rating in a report on Friday, July 11th. Seventeen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $63.94.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.